CORRESPONDENCE

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

TO THE EDITOR: On November 26, 2021, the World Health Organization (WHO) named the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in South Africa, as a variant of concern.¹ By November 29, 2021, three days after the announcement by the WHO, cases of infection with the omicron variant had already been detected in many other countries.


Whether the BNT162b2 vaccine (Pfizer– BioNTech), which was previously shown to have 95% efficacy against coronavirus disease 2019 (Covid-19),^{2,3} will effectively neutralize infection with the omicron variant is unclear. We compared neutralization of omicron-infected cells in serum samples obtained from participants who had received two doses of vaccine with neutralization in samples obtained from participants who had received three doses.

Microneutralization assays with wild-type virus and B.1.351 (beta), B.1.617.2 (delta), and omicron variant isolates were performed with the use of serum samples obtained from two groups of 20 health care workers. One group comprised participants who had received two doses of the BNT162b2 vaccine (mean, 165.6 days since receipt of the second dose), and the second group comprised those who had received three vaccine doses (mean, 25 days since receipt of the third dose) (Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Significance was assessed with the use of a Wilcoxon matched-pairs signed-rank test.

Receipt of three vaccine doses led to better neutralization of the wild-type virus and the three variants than receipt of two vaccine doses (Fig. 1). The geometric mean titers of the wildtype virus and the beta, delta, and omicron vari-

ants were 16.56, 1.27, 8.00, and 1.11, respectively, after receipt of the second vaccine dose and 891.4, 152.2, 430.5, and 107.6, respectively, after receipt of the third dose. A significantly lower neutralization efficiency of the BNT162b2 vaccine against all the tested variants of concern (beta, delta, and omicron) than against the wildtype virus was observed in samples obtained from participants who had received two doses than in those obtained from participants who had received three doses (Fig. 1B and 1D). The lower neutralization efficiency against the beta and omicron variants than against the wild-type virus was similar in samples obtained from participants who had received two doses and in those obtained from participants who had received three doses. The third dose of the BNT162b2 vaccine efficiently neutralized infection with the omicron variant (geometric mean titer, 1.11 after the second dose vs. 107.6 after the third dose) (Fig. 1A and 1C).

We analyzed the neutralization efficiency of the BNT162b2 vaccine against wild-type SARS-CoV-2 and the beta, delta, and omicron variants of concern. Limitations of the study include the small cohort tested and the fact that the test was only an in vitro assay. Nevertheless, we found low neutralization efficiency with two doses of the BNT162b2 vaccine against the wild-type virus and the delta variant, assessed more than 5 months after receipt of the second dose, and no neutralization efficiency against the omicron variant. The importance of a third vaccine dose is clear, owing to the higher neutralization efficiency (by a factor of 100) against the omicron variant after the third dose than after the second dose; however, even with three vaccine doses, neutralization against the omicron variant was lower (by a factor of 4) than that against the



delta variant. The durability of the effect of the third dose of vaccine against Covid-19 is yet to be determined.

Ital Nemet, Ph.D. Limor Kliker, M.Sc. Yaniv Lustig, Ph.D. Neta Zuckerman, Ph.D. Oran Erster, Ph.D. Ministry of Health Ramat Gan, Israel

Carmit Cohen, Ph.D.

Yitshak Kreiss, M.D. Sheba Medical Center Tel Hashomer

Ramat Gan, Israel

Sharon Alroy-Preis, M.D.

Ministry of Health Jerusalem, Israel

Gili Regev-Yochay, M.D.

Sheba Medical Center Tel Hashomer Ramat Gan, Israel

Ella Mendelson, Ph.D.

Michal Mandelboim, Ph.D.

Ministry of Health Ramat Gan, Israel

michal.mandelboim@sheba.health.gov.il

Dr. Nemet and Ms. Kliker, and Drs. Mendelson and Mandelboim, contributed equally to this letter.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on December 29, 2021, at NEJM.org.

1. World Health Organization. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. November 26, 2021

(https://www.who.int/news/item/26-11-2021-classification-of -omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).

2. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021;385:1393-400.

3. Haas EJ, McLaughlin JM, Khan F, et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis 2021 September 22 (Epub ahead of print).

DOI: 10.1056/NEJMc2119358

Correspondence Copyright © 2021 Massachusetts Medical Society.